Krystal Biotech, Inc. (KRYS) stock
KRYSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 11/3052% above fair value
$298.55+0.65 (+0.22%)
Close on Nov 17, 2026Market cap $8.84BP/E 37.4Yield –
Krystal Biotech r&d expenses
Research and development expenses are spending on new products and technology.
Krystal Biotech's R&D Expenses for the twelve months ending Jun 30, 2026 was $59.23M, up 6.3% year over year. For fiscal 2025 it was $58.05M, up 8.3% from the year before. The highest annual figure on record is $58.05M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $58.05M | +8.3% |
| FY2024 | Dec 31, 2024 | $53.58M | +15.4% |
| FY2023 | Dec 31, 2023 | $46.43M | +9.4% |
| FY2022 | Dec 31, 2022 | $42.46M | +52.3% |
| FY2021 | Dec 31, 2021 | $27.88M | +55.5% |
| FY2020 | Dec 31, 2020 | $17.94M | +14.9% |
| FY2019 | Dec 31, 2019 | $15.62M | +101.2% |
| FY2018 | Dec 31, 2018 | $7.76M | +141.9% |
| FY2017 | Dec 31, 2017 | $3.21M | +332.9% |
| FY2016 | Dec 31, 2016 | $741.00K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $14.52M | +0.7% |
| Q1 FY2026 | Mar 31, 2026 | $15.33M | +7.5% |
| Q4 FY2025 | Dec 31, 2025 | $14.79M | +9.4% |
| Q3 FY2025 | Sep 30, 2025 | $14.59M | +7.9% |
| Q2 FY2025 | Jun 30, 2025 | $14.41M | -7.5% |
| Q1 FY2025 | Mar 31, 2025 | $14.26M | +30.1% |
| Q4 FY2024 | Dec 31, 2024 | $13.53M | +19.0% |
| Q3 FY2024 | Sep 30, 2024 | $13.51M | +27.1% |
| Q2 FY2024 | Jun 30, 2024 | $15.58M | +28.3% |
| Q1 FY2024 | Mar 31, 2024 | $10.96M | -10.8% |
| Q4 FY2023 | Dec 31, 2023 | $11.37M | +5.9% |
| Q3 FY2023 | Sep 30, 2023 | $10.63M | -7.7% |
| Q2 FY2023 | Jun 30, 2023 | $12.14M | +11.5% |
| Q1 FY2023 | Mar 31, 2023 | $12.29M | +31.9% |
| Q4 FY2022 | Dec 31, 2022 | $10.74M | +19.2% |
| Q3 FY2022 | Sep 30, 2022 | $11.52M | +89.4% |
| Q2 FY2022 | Jun 30, 2022 | $10.89M | +65.2% |
| Q1 FY2022 | Mar 31, 2022 | $9.31M | +50.2% |
| Q4 FY2021 | Dec 31, 2021 | $9.01M | +58.8% |
| Q3 FY2021 | Sep 30, 2021 | $6.08M | +19.2% |
| Q2 FY2021 | Jun 30, 2021 | $6.59M | +81.2% |
| Q1 FY2021 | Mar 31, 2021 | $6.20M | +75.9% |
| Q4 FY2020 | Dec 31, 2020 | $5.67M | +30.4% |
| Q3 FY2020 | Sep 30, 2020 | $5.10M | +31.3% |
| Q2 FY2020 | Jun 30, 2020 | $3.64M | -13.7% |
| Q1 FY2020 | Mar 31, 2020 | $3.53M | +11.3% |
| Q4 FY2019 | Dec 31, 2019 | $4.35M | +55.2% |
| Q3 FY2019 | Sep 30, 2019 | $3.89M | +103.0% |
| Q2 FY2019 | Jun 30, 2019 | $4.22M | +176.5% |
| Q1 FY2019 | Mar 31, 2019 | $3.17M | +108.4% |
| Q4 FY2018 | Dec 31, 2018 | $2.80M | +157.5% |
| Q3 FY2018 | Sep 30, 2018 | $1.91M | +41.3% |
| Q2 FY2018 | Jun 30, 2018 | $1.53M | +241.9% |
| Q1 FY2018 | Mar 31, 2018 | $1.52M | +376.5% |
| Q4 FY2017 | Dec 31, 2017 | $1.09M | +170.6% |
| Q3 FY2017 | Sep 30, 2017 | $1.36M | +462.2% |
| Q2 FY2017 | Jun 30, 2017 | $446.00K | – |
| Q1 FY2017 | Mar 31, 2017 | $319.00K | – |
| Q4 FY2016 | Dec 31, 2016 | $402.00K | – |
| Q3 FY2016 | Sep 30, 2016 | $241.00K | – |
See a number that looks wrong?